These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

314 related items for PubMed ID: 23740187

  • 1. Treatment choices of paediatric rheumatologists for juvenile idiopathic arthritis: etanercept or adalimumab?
    Anink J, Otten MH, Gorter SL, Prince FH, van Rossum MA, van den Berg JM, van Pelt PA, Kamphuis S, Brinkman DM, Swen WA, Swart JF, Wulffraat NM, Dolman KM, Koopman-Keemink Y, Hoppenreijs EP, Armbrust W, ten Cate R, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Sep; 52(9):1674-9. PubMed ID: 23740187
    [Abstract] [Full Text] [Related]

  • 2. Tumour necrosis factor-blocking agents in persistent oligoarticular juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children Register.
    Anink J, Otten MH, Prince FH, Hoppenreijs EP, Wulffraat NM, Swart JF, ten Cate R, van Rossum MA, van den Berg JM, Dolman KM, Koopman-Keemink Y, Armbrust W, Kamphuis S, van Pelt PA, Gorter SL, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2013 Apr; 52(4):712-7. PubMed ID: 23267169
    [Abstract] [Full Text] [Related]

  • 3. Experiences with tumour necrosis factor-{alpha} inhibitors in patients with juvenile idiopathic arthritis: Hungarian data from the National Institute of Rheumatology and Physiotherapy Registry.
    Sevcic K, Orban I, Brodszky V, Bazso A, Balogh Z, Poor G, Kiss E.
    Rheumatology (Oxford); 2011 Jul; 50(7):1337-40. PubMed ID: 21372001
    [Abstract] [Full Text] [Related]

  • 4. Tumor necrosis factor-blocking agents for children with enthesitis-related arthritis--data from the dutch arthritis and biologicals in children register, 1999-2010.
    Otten MH, Prince FH, Twilt M, Ten Cate R, Armbrust W, Hoppenreijs EP, Koopman-Keemink Y, Wulffraat NM, Gorter SL, Dolman KM, Swart JF, van den Berg JM, van Rossum MA, van Suijlekom-Smit LW.
    J Rheumatol; 2011 Oct; 38(10):2258-63. PubMed ID: 21844151
    [Abstract] [Full Text] [Related]

  • 5. Effectiveness and safety of a second and third biological agent after failing etanercept in juvenile idiopathic arthritis: results from the Dutch National ABC Register.
    Otten MH, Prince FH, Anink J, Ten Cate R, Hoppenreijs EP, Armbrust W, Koopman-Keemink Y, van Pelt PA, Kamphuis S, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2013 May; 72(5):721-7. PubMed ID: 22730374
    [Abstract] [Full Text] [Related]

  • 6. Trends in prescription of biological agents and outcomes of juvenile idiopathic arthritis: results of the Dutch national Arthritis and Biologics in Children Register.
    Otten MH, Anink J, Prince FH, Twilt M, Vastert SJ, ten Cate R, Hoppenreijs EP, Armbrust W, Gorter SL, van Pelt PA, Kamphuis SS, Dolman KM, Swart JF, van den Berg JM, Koopman-Keemink Y, van Rossum MA, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2015 Jul; 74(7):1379-86. PubMed ID: 24641940
    [Abstract] [Full Text] [Related]

  • 7. Tumour necrosis factor (TNF)-blocking agents in juvenile psoriatic arthritis: are they effective?
    Otten MH, Prince FH, Ten Cate R, van Rossum MA, Twilt M, Hoppenreijs EP, Koopman-Keemink Y, Oranje AP, de Waard-van der Spek FB, Gorter SL, Armbrust W, Dolman KM, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2011 Feb; 70(2):337-40. PubMed ID: 21068101
    [Abstract] [Full Text] [Related]

  • 8. Long-term follow-up on effectiveness and safety of etanercept in juvenile idiopathic arthritis: the Dutch national register.
    Prince FH, Twilt M, ten Cate R, van Rossum MA, Armbrust W, Hoppenreijs EP, van Santen-Hoeufft M, Koopman-Keemink Y, Wulffraat NM, van Suijlekom-Smit LW.
    Ann Rheum Dis; 2009 May; 68(5):635-41. PubMed ID: 18413443
    [Abstract] [Full Text] [Related]

  • 9. Tumor necrosis factor-alpha blocker in treatment of juvenile idiopathic arthritis-associated uveitis refractory to second-line agents: results of a multinational survey.
    Foeldvari I, Nielsen S, Kümmerle-Deschner J, Espada G, Horneff G, Bica B, Olivieri AN, Wierk A, Saurenmann RK.
    J Rheumatol; 2007 May; 34(5):1146-50. PubMed ID: 17343318
    [Abstract] [Full Text] [Related]

  • 10. Direct comparison of treatment responses, remission rates, and drug adherence in patients with rheumatoid arthritis treated with adalimumab, etanercept, or infliximab: results from eight years of surveillance of clinical practice in the nationwide Danish DANBIO registry.
    Hetland ML, Christensen IJ, Tarp U, Dreyer L, Hansen A, Hansen IT, Kollerup G, Linde L, Lindegaard HM, Poulsen UE, Schlemmer A, Jensen DV, Jensen S, Hostenkamp G, Østergaard M, All Departments of Rheumatology in Denmark.
    Arthritis Rheum; 2010 Jan; 62(1):22-32. PubMed ID: 20039405
    [Abstract] [Full Text] [Related]

  • 11. Efficacy of etanercept for the treatment of juvenile idiopathic arthritis according to the onset type.
    Quartier P, Taupin P, Bourdeaut F, Lemelle I, Pillet P, Bost M, Sibilia J, Koné-Paut I, Gandon-Laloum S, LeBideau M, Bader-Meunier B, Mouy R, Debré M, Landais P, Prieur AM.
    Arthritis Rheum; 2003 Apr; 48(4):1093-101. PubMed ID: 12687553
    [Abstract] [Full Text] [Related]

  • 12. Anaphylaxis to etanercept in two children with juvenile idiopathic arthritis.
    Crayne CB, Gerhold K, Cron RQ.
    J Clin Rheumatol; 2013 Apr; 19(3):129-31. PubMed ID: 23519173
    [Abstract] [Full Text] [Related]

  • 13. Etanercept and uveitis in patients with juvenile idiopathic arthritis.
    Schmeling H, Horneff G.
    Rheumatology (Oxford); 2005 Aug; 44(8):1008-11. PubMed ID: 15855187
    [Abstract] [Full Text] [Related]

  • 14. Development of inflammatory bowel disease in patients with juvenile idiopathic arthritis treated with etanercept.
    van Dijken TD, Vastert SJ, Gerloni VM, Pontikaki I, Linnemann K, Girschick H, Armbrust W, Minden K, Prince FH, Kokke FT, Nieuwenhuis EE, Horneff G, Wulffraat NM.
    J Rheumatol; 2011 Jul; 38(7):1441-6. PubMed ID: 21459936
    [Abstract] [Full Text] [Related]

  • 15. Adalimumab, etanercept, and infliximab utilization patterns and drug costs among rheumatoid arthritis patients.
    Carter CT, Changolkar AK, Scott McKenzie R.
    J Med Econ; 2012 Jul; 15(2):332-9. PubMed ID: 22168788
    [Abstract] [Full Text] [Related]

  • 16. Factors associated with treatment response to etanercept in juvenile idiopathic arthritis.
    Otten MH, Prince FH, Armbrust W, ten Cate R, Hoppenreijs EP, Twilt M, Koopman-Keemink Y, Gorter SL, Dolman KM, Swart JF, van den Berg JM, Wulffraat NM, van Rossum MA, van Suijlekom-Smit LW.
    JAMA; 2011 Dec 07; 306(21):2340-7. PubMed ID: 22056397
    [Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of adalimumab as the first and second biologic agent in juvenile idiopathic arthritis: the German Biologics JIA Registry.
    Schmeling H, Minden K, Foeldvari I, Ganser G, Hospach T, Horneff G.
    Arthritis Rheumatol; 2014 Sep 07; 66(9):2580-9. PubMed ID: 24942886
    [Abstract] [Full Text] [Related]

  • 18. Drug survival of the first and second course of anti-tumour necrosis factor agents in juvenile idiopathic arthritis.
    Tynjälä P, Vähäsalo P, Honkanen V, Lahdenne P.
    Ann Rheum Dis; 2009 Apr 07; 68(4):552-7. PubMed ID: 18467515
    [Abstract] [Full Text] [Related]

  • 19. An analysis of the costs and treatment success of etanercept in juvenile idiopathic arthritis: results from the Dutch Arthritis and Biologicals in Children register.
    Prince FH, de Bekker-Grob EW, Twilt M, van Rossum MA, Hoppenreijs EP, ten Cate R, Koopman-Keemink Y, Gorter SL, Raat H, van Suijlekom-Smit LW.
    Rheumatology (Oxford); 2011 Jun 07; 50(6):1131-6. PubMed ID: 21278067
    [Abstract] [Full Text] [Related]

  • 20. Infliximab and etanercept in the treatment of chronic uveitis associated with refractory juvenile idiopathic arthritis.
    Tynjälä P, Lindahl P, Honkanen V, Lahdenne P, Kotaniemi K.
    Ann Rheum Dis; 2007 Apr 07; 66(4):548-50. PubMed ID: 17068061
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.